Unraveling the Complexity of Polycystic Ovary Syndrome (PCOS):

A Comprehensive Review

Veerabhadrappa G. Mendagudli

Principal, BLDEA'S College of Nursing, Jamkhandi. Karnataka State. India.

*Corresponding Author Email: veerabhadrappa.bijapur@gmail.com

ABSTRACT:

A common endocrine condition affecting individuals of reproductive age, polycystic ovary syndrome (PCOS) is defined by a range of clinical, hormonal, and metabolic features. With regard to PCOS, this review article seeks to give a thorough summary of the disease's aetiology, clinical presentation, diagnostic criteria, and available treatments. The prevalence of PCOS among women who are fertile is estimated to be between 5% and 20% worldwide. It is widely recognized that this disease is complicated, involving both environmental factors and genetic predisposition. Often present clinical signs include irregular menstruation, hyperandrogenism, and polycystic ovarian morphology on ultrasonography. Although there are a number of diagnostic criteria sets available, including the Rotterdam criteria and the National Institutes of Health standards, a precise diagnosis is still necessary. Among the metabolic problems that are more prone to occur in PCOS patients are insulin resistance, dyslipidemia, and obesity. Increased risk of heart disease, type 2 diabetes, and infertility are among the long-term health consequences. Therapeutic approaches, which include both lifestyle modifications and pharmacological therapy and are tailored to the patient's presentation and goals, primarily aim to improve hormonal imbalances, metabolic abnormalities, and reproductive outcomes. In order to improve healthcare professionals' comprehension of PCOS, this review compiles the most recent scientific findings and clinical insights.

KEYWORDS: Polycystic Ovary Syndrome, PCOS, Hyperandrogenism, Insulin resistance, Metabolic syndrome, Lifestyle modifications, Personalized medicine.

INTRODUCTION:

Polycystic ovarian syndrome (PCOS) is a complex endocrine disorder that affects women's health globally. Since Stein and Leventhal first described it in 1935, the aetiology and clinical signs have been extensively studied. PCOS symptoms include polycystic ovaries on ultrasound imaging, irregular menstrual cycles, and hyperandrogenism.

Polycystic Ovary Disease (PCOD), also known as Polycystic Ovary Syndrome (PCOS), is a common endocrine disorder affecting individuals with ovaries. It is characterized by a combination of hormonal imbalances, metabolic disturbances, and reproductive issues.

What do you mean by Polycystic ovary syndrome (PCOS)?

Patients with polycystic ovarian syndrome (PCOS) have an abnormally high production of androgens, male sex hormones that are normally present in women in small amounts. The phrase "polycystic ovarian syndrome" describes a collection of microscopic cysts, or sacs filled with fluid, that form in the ovaries.

What causes PCOS, or polycystic ovarian syndrome?

· Despite the fact that the precise cause of PCOS is unknown, it often runs in families.

· It has to do with the hormone imbalances in the body, including high insulin levels.

· The body's sugar levels are regulated by the hormone insulin.

· A lot of PCOS sufferers produce more insulin in an effort to overcome their body's resistance to it.

Pathophysiology:

Although the precise etiology of PCOS is still unknown, a combination of hormonal, environmental, and genetic factors are considered to be involved in its development. Insulin resistance and hyperinsulinemia are common findings in PCOS patients, and both conditions can lead to compensatory hyperandrogenism and ovarian dysfunction. The relevance of inflammation and malfunctioning adipose tissue in the aetiology of PCOS has also been underscored by recent study.

Clinical Features:

1. Menstrual irregularities: oligomenorrhea (infrequent menstrual periods) or amenorrhea (absence of menstrual periods).

2. Hyperandrogenism: hirsutism, acne, male-pattern baldness.

3. Polycystic ovaries on ultrasound: multiple small cysts on the ovaries.

Diagnostic Criteria:

The Rotterdam criteria (2003) are commonly used for diagnosis, requiring the presence of two out of three criteria: oligo/anovulation, clinical/biochemical signs of hyperandrogenism, and polycystic ovaries on ultrasound.

Associated Conditions:

1. Insulin resistance and metabolic syndrome.

2. Obesity is often associated with PCOS.

3. Increased risk of type 2 diabetes, cardiovascular disease, and endometrial cancer.

Management:

· Lifestyle modifications: Weight loss, exercise, and a healthy diet can improve insulin sensitivity.

· Medications: Hormonal contraceptives, anti-androgens, and insulin-sensitizing agents may be prescribed.

· Fertility treatments: for those trying to conceive.

Future Directions:

Research is continuously being done to identify novel targets for treatment and to decipher the complex pathophysiology of PCOS. With the use of phenotypic traits and genetic predisposition, personalised medicine improvements may result in more specific techniques of diagnosis and therapy. The long-term cardiovascular and metabolic issues associated with PCOS are also being investigated and merit more investigation.

CONCLUSION:

In conclusion, polycystic ovarian syndrome is a prevalent endocrine disorder that presents with a wide range of clinical symptoms. Comprehending the pathophysiology of the condition and implementing appropriate diagnostic and therapeutic measures are essential for enhancing the quality of life for individuals impacted. More research is needed to address the problems brought on by PCOS, and collaboration between medical professionals, researchers, and lawmakers is also necessary.

REFERENCES:

1. Teede HJ, Misso ML, Costello MF, et al. International PCOS Network. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Clin Endocrinol (Oxf). 2018;89(3):251-268.

2. Chen ZJ, Shi Y, Sun Y, et al. Fresh versus Frozen Embryos for Infertility in the Polycystic Ovary Syndrome. N Engl J Med. 2016;375(6):523-533.

3. Talbott EO, Zborowski J, Rager J, et al. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2004;89(11):5454-5461.

4. Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016; 2:16057.

5. Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33(6):981-1030.

6. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol. 1935;29(2):181-191.

7. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18(6):774-800.

8. Shivaleela S. Sarawad. Polycystic Ovary Syndrome (PCOS): A Comprehensive Review. International Journal of Advances in Nursing Management. 2023; 11(4):264-5. doi: 10.52711/2454-2652.2023.00059

9. Domecq JP, Prutsky G, Mullan RJ, et al. Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-analysis. J Clin Endocrinol Metab. 2013;98(12):4655-4663.

Received on 15.01.2024 Revised on 16.09.2024

Accepted on 31.01.2025 Published on 24.02.2025

Available online from March 17, 2025

Asian J. Nursing Education and Research. 2025;15(1):67-68.

DOI: 10.52711/2349-2996.2025.00015

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.